CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
The disclosures made below under Item 7.01, Regulation FD Disclosure, are incorporated by reference into this Item 2.02.
Item 7.01.Regulation FD Disclosure.
On March 19, 2018, CytRx Corporation (the "Company") announced its financial results for the year ended December 31, 2017, and provided highlights of 2018 corporate activities. Attached as Exhibit 99.1 to this Current Report on Form 8-K is the press release issued by the Company on March 19, 2018, which is incorporated herein by reference.
As described in the press release, the Company will hold a webcast to discuss the 2017 financial results and recent 2018 highlights. A replay of the webcast will be posted on the Company's website: www.cytrx.com.
The information in this Item 7.01 and Exhibit 99.1 to this Report shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01.Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 19, 2018 |
CYTRX CORP ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE DATED MARCH 19,…To view the full exhibit click here
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
